Currently, the vaccine is not approved for that age group, but it is approved for use in children over the age of 12 in both the United States and the European Union.
Earlier this month, the two companies requested US regulators to grant an emergency use authorization for shots for young children, and a US Food and Drug Administration advisory board will meet next month to review the data.
Children are less susceptible to severe COVID-19, but can spread the virus to others, including vulnerable populations at high risk of serious illness.
The Pfizer / BioNTech vaccine has been shown in clinical trials with 2,268 participants to elicit a strong immune response between the ages of 5 and 11, the two companies said on September 20.
Pfizer / BioNTech submits data for infant COVID-19 vaccine to EMA, Health News, ET Health World
Source link Pfizer / BioNTech submits data for infant COVID-19 vaccine to EMA, Health News, ET Health World